UniSuper Management Pty Ltd Sells 124,258 Shares of Gilead Sciences, Inc. $GILD

UniSuper Management Pty Ltd cut its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 22.1% in the 4th quarter, HoldingsChannel.com reports. The firm owned 437,734 shares of the biopharmaceutical company’s stock after selling 124,258 shares during the period. UniSuper Management Pty Ltd’s holdings in Gilead Sciences were worth $53,727,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in GILD. Norges Bank bought a new stake in Gilead Sciences in the 4th quarter valued at $2,617,152,000. Massachusetts Financial Services Co. MA boosted its stake in Gilead Sciences by 3,763.8% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock valued at $518,368,000 after purchasing an additional 4,113,999 shares during the period. Vanguard Group Inc. boosted its stake in Gilead Sciences by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock valued at $14,863,487,000 after purchasing an additional 2,113,692 shares during the period. First Trust Advisors LP boosted its stake in Gilead Sciences by 154.3% in the 3rd quarter. First Trust Advisors LP now owns 3,089,283 shares of the biopharmaceutical company’s stock valued at $342,910,000 after purchasing an additional 1,874,508 shares during the period. Finally, Invesco Ltd. boosted its stake in Gilead Sciences by 12.0% in the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock valued at $1,680,505,000 after purchasing an additional 1,618,453 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the sale, the insider directly owned 125,779 shares in the company, valued at $16,513,524.91. This represents a 18.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the sale, the chief executive officer owned 617,567 shares of the company’s stock, valued at approximately $81,185,357.82. This represents a 2.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 68,000 shares of company stock worth $9,047,570 in the last ninety days. 0.30% of the stock is owned by insiders.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead and Merck reported positive topline Phase 3 results for their once-weekly oral HIV regimen (islatravir + lenacapavir), reinforcing optimism around Gilead’s HIV franchise and future growth. Is Gilead (GILD) One of the Top Large Cap Value Stocks to Buy Now?
• Positive Sentiment: Bernstein reiterated a Buy rating on Gilead, which can help sentiment by signaling confidence in the company’s outlook. Gilead Sciences (GILD) Gets a Buy from Bernstein
• Positive Sentiment: Options activity skewed bullish, with unusually high call buying, suggesting traders were positioning for more upside in GILD.
• Positive Sentiment: Recent articles also highlighted progress in Gilead’s pipeline, including Livdelzi Phase 3 results and strength in its HIV franchise, both of which support the stock’s growth narrative. Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline Development
• Neutral Sentiment: The Gilead Foundation announced a roughly $3 million, three-year commitment with the National AIDS Memorial to expand HIV/AIDS education and community leadership, a reputationally positive move but not a direct earnings driver. National AIDS Memorial and the Gilead Foundation Launch Major Investment…
• Negative Sentiment: Erste Group Bank slightly lowered its FY2026 EPS estimate for Gilead, reflecting a modestly less optimistic near-term profit outlook.

Gilead Sciences Price Performance

Shares of GILD stock opened at $125.87 on Friday. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a twelve month low of $104.46 and a twelve month high of $157.29. The company has a market cap of $156.28 billion, a P/E ratio of 17.15 and a beta of 0.31. The business has a fifty day simple moving average of $133.46 and a 200 day simple moving average of $134.34.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same period in the prior year, the company earned $1.81 EPS. Gilead Sciences’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post -0.79 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio is currently 44.69%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on GILD. Jefferies Financial Group began coverage on Gilead Sciences in a research report on Tuesday, March 10th. They set a “buy” rating and a $180.00 target price for the company. Argus upped their target price on Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. The Goldman Sachs Group upped their target price on Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research report on Friday, April 17th. Citigroup upped their target price on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Gilead Sciences in a research report on Tuesday. Twenty-five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $156.93.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.